grazoprevir: Clinical Trials

10 trials of grazoprevir, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 2 withdrawn, 1 terminated. 10 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 410Completed 7, Withdrawn 2, Terminated 1

Follow grazoprevir: new trials by email Literature Review of grazoprevir trials Research Report on grazoprevir

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4
Elbasvir/Grazoprevir 50 MG-100 MG Oral Tablet [ZEPATIER] - Hepatitis C Virus Infection, Response to Therapy of
Phase 4WithdrawnUniversity of Maryland, Baltimore2019-12-012020-04-20
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Elbasvir 50 MG / Grazoprevir 100 MG [Zepatier] - Hepatitis C, Hemodialysis
Phase 4CompletedUniversity of Pennsylvania62019-09-222021-12-15
Grazoprevir/Elbasvir for Genotype 1b Chronic Hepatitis C After Liver or Kidney Transplantation
grazoprevir 100 mg/ elbasvir 50 mg, Zepatier® - Chronic Hepatitis c, Liver Transplant Infection
Phase 4TerminatedTaichung Veterans General Hospital142019-02-142021-03-16
Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication
Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI - Cardiovascular Diseases, Hepatitis C
Phase 4CompletedUniversity of Maryland, Baltimore872018-11-182023-05-22
Preemptive Zepatier Treatment in Donor HCV Positive to Recipient HCV Negative Cardiac Transplant
Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin - Cardiac Transplant Disorder, Hepatitis C
Phase 4WithdrawnRaymond T. Chung, MD2018-08-012018-12-20
Efficacy and Tolerability of Grazoprevir and Elbasvir in Patients With Chronic Genotype 1 HCV and HIV Co-infection
grazoprevir and elbasvir - Chronic Hepatitis C
Phase 4CompletedTaoyuan General Hospital402017-10-202018-12-20
A Study for G1b CHC Patients With CKD-3 Treated With Grazoprevir Plus Elbasvir
Grazoprevir plus Elbasvir - Hepatitis C Viral, Chronic Kidney Disease stage3
Phase 4CompletedKyushu University802017-04-012019-06-03
Preemptive Treatment With Grazoprevir and Elbasvir for Donor HCV Positive to Recipient HCV Negative Kidney Transplant
elbasvir (50mg) / grazoprevir (100mg) (fixed dose combination) - Renal Failure
Phase 4CompletedMassachusetts General Hospital82017-02-012020-06-09
Exploring Renal Transplants Using Hepatitis C Infected Donors for HCV-negative Recipients
Zepatier, Ribavirin, Sofosbuvir - End-Stage Renal Disease, Hepatitis C
Phase 4CompletedJohns Hopkins University102016-07-202018-09-06
Study of Oral Treatments for Hepatitis C
SOF/LDV (sofosbuvir/ledipasvir), PrOD (ombitasvir/paritaprevir/ritonavir with dasabuvir) (Phase 1 only), EBR/GZR (elbasvir/grazoprevir) - Chronic Hepatitis C
Phase 4CompletedUniversity of Florida12752016-06-012021-12-06

Conditions studied

Hepatitis C (7)  ·  Hepatitis C, Chronic (3)  ·  Kidney Failure, Chronic (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Cardiovascular Diseases (1)  ·  Cross Infection (1)  ·  Renal Insufficiency (1)

Sponsors

University of Maryland, Baltimore (2)  ·  Johns Hopkins University (1)  ·  Kyushu University (1)  ·  Massachusetts General Hospital (1)  ·  Raymond T. Chung, MD (1)  ·  Taichung Veterans General Hospital (1)  ·  Taoyuan General Hospital (1)  ·  University of Florida (1)  ·  University of Pennsylvania (1)

Countries

United States (6)  ·  Taiwan (2)  ·  Egypt (1)  ·  Japan (1)

Top investigators

Chien-Yu Cheng (1)  ·  David R Nelson, MD (1)  ·  Michael R Rudnick, MD (1)  ·  Norihiro Furusyo, MD, PhD (1)  ·  Poonam Mathur, DO (1)  ·  Raymond Chung, MD (1)  ·  Raymond T Chung, MD (1)  ·  Shyamasundaran Kottilil, MD, PhD (1)  ·  Teng-Yu Lee, MD (1)

Results publications

PMID 24073301, PMID 25909356, PMID 27720838, PMID 28193518, PMID 29507971, PMID 31114268, PMID 34255381, PMID 34902265, PMID 35182741, PMID 35657133